Pain Management Drugs Market Report 2025

The pain management drugs market size has grown strongly in recent years. It will grow from $80.13 billion in 2024 to $84.51 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to rising chronic pain cases, rise in cancer cases, increased surgical procedures, improved pain assessment, government initiatives.

The pain management drugs market size is expected to see strong growth in the next few years. It will grow to $106.56 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to non-opioid alternatives, targeted therapies, precision medicine approaches, psychological interventions, focus on minimizing side effects. Major trends in the forecast period include value-based care models, expanded access programs, combination therapies, innovative formulations, biosimilar pain drugs.

An increasing number of surgeries is anticipated to boost the growth of the pain management drugs market in the future. A surgical procedure involves medical intervention that requires cutting or penetrating the body's tissues to treat diseases, conditions, or injuries, or to alter bodily functions or enhance appearance. Pain management drugs are essential in surgeries as they help control and alleviate post-operative pain, significantly enhancing patient comfort and recovery. For example, in September 2023, the International Society of Aesthetic Plastic Surgery, a US-based professional organization for board-certified aesthetic plastic surgeons, released the Global Survey 2022 report, which revealed an 11.2% overall increase in procedures performed by plastic surgeons in 2022, totaling over 14.9 million surgical procedures worldwide. There has been a consistent rise in aesthetic surgery over the past four years, showing a 41.3% increase. Therefore, the rising rate of surgeries is driving the growth of the pain management drugs market.

The growth of the pain management drugs market is further expected to be boosted by the rise in the geriatric population. The geriatric population, comprising individuals aged 65 and older, often requires pain management drugs to alleviate conditions such as arthritis, cancer, and neurological disorders that are more prevalent in later life. According to a report by the World Health Organization (WHO) in October 2022, it is projected that by 2030, one in six individuals globally will be 60 years or older, and the number of individuals over 60 will double to 2.1 billion by 2050. Additionally, between 2020 and 2050, there will be an increase of 426 million people aged 80 or older. This demographic shift toward an aging population is a driving force behind the growth of the pain management drugs market.

Technological advancement is a prominent trend gaining traction in the pain management drugs market. Major companies in this sector are concentrating on the development of new technologies. For example, in October 2024, Vertex Pharmaceuticals, a US-based biotechnology firm, announced substantial progress in Suzetrigine (VX-548) for treating acute and neuropathic pain. This innovative medication aims to deliver effective pain relief while minimizing the side effects typically associated with conventional analgesics. The development of Suzetrigine is expected to expand treatment options for patients experiencing various pain conditions, thereby enhancing their quality of life. By advancing this cutting-edge therapy, Vertex seeks to address unmet medical needs in pain management and establish itself as a leader in the pharmaceutical industry.

Major companies in the pain management drugs market are developing drugs and obtaining FDA approval. FDA approval, indicating adherence to safety and efficacy standards, is crucial for commercial distribution in the United States. For instance, in October 2023, Hyloris Pharmaceuticals, a Belgium-based pharmaceutical company, received FDA approval for Maxigesic IV. This non-opioid intravenous painkiller, combining paracetamol and ibuprofen, offers a dual-action mechanism for pain relief and represents a significant advancement in the market, providing a new non-opioid treatment option for post-operative pain relief.

In October 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology firm, acquired Biohaven Pharmaceuticals Inc. for an undisclosed sum. This acquisition is intended to strengthen Pfizer's portfolio in the neurology sector, specifically focusing on the development and commercialization of innovative treatments for neurological disorders. Biohaven Pharmaceuticals Inc. is a US-based biotechnology research company specializing in the development of pain management drugs.

Major companies operating in the pain management drugs market include Novartis AG, Eli Lilly And Company, Abbott Laboratories, Endo International plc, Pfizer Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., GlaxoSmithKline plc, AbbVie Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bausch Health Companies Inc., Sanofi, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim, Mallinckrodt Pharmaceuticals, Daiichi Sankyo Company Limited, Grünenthal GmbH, Mundipharma International Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Zydus Cadila, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd.

North America was the largest region in the pain management drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the pain management drug market report during the forecast period. The regions covered in the pain management drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pain management drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A pain management drug is a medication designed to reduce pain, achieving analgesia through actions at multiple levels of the nervous system. These actions include the inhibition of neurotransmitter release from the primary afferent terminals in the spinal cord and the activation of descending inhibitory controls in the midbrain.

The primary classes of pain management drugs comprise non-steroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. NSAIDs, or nonsteroidal anti-inflammatory drugs, are specifically designed to lower a high fever, reduce inflammation, and alleviate discomfort. They find application in various conditions such as arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, muscle sprain/strain, bone fractures, among others. These drugs are distributed through different channels including hospital pharmacies, retail pharmacies, and online pharmacies.

The pain management drugs market research report is one of a series of new reports that provides pain management drugs market statistics, including pain management drugs industry global market size, regional shares, competitors with a pain management drugs market share, detailed pain management drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the pain management drugs industry. This pain management drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pain management drug market consists of sales of acetaminophen, anti-seizure medications, steroids, muscle relaxers, and other related drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.